Pfizer vaccine likely to work against new, rapidly-spreading variants: Study
A new study says Pfizer's vaccine is likely to work against the new, rapidly-spreading variants of COVID-19.
Dr. Pei-Yong Shi of the University of Texas Medical Branch in Galveston told ABC News this is "the first study to show that one of the most prominent mutations in the fast-spreading UK and the South African strain ... doesn't affect the neutralizing activity of the current vaccine."
Some of the antibodies produced by the vaccine "may be weakened by a single mutation, but others will remain active," he said, which he believes will continue to provide protection from the variants.
Although Shi only studied Pfizer's vaccine, he said the results "can be generated to the other vaccine platforms," including Moderna and AstraZeneca.
The vaccines “are all based on the same sequence of the spike protein,” he said, “so I will not be surprised that it will be it will be the same result."
While the U.K. variant that’s been confirmed in several U.S. states appears to spread more rapidly, there’s no evidence that it’s more deadly.
ABC News’ Sony Salzman contributed to this report.